The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Circulating Tumor Cells (CTCs) Prognostic Technologies-Global Market Insights and Sales Trends 2024
Synopsis
Circulating tumor cells (CTCs) are specialized rare cells, which have been shed from a primary solid tumor of the body and circulate in the vasculature system of the body, eventually causing metastasis. CTCs act as the seeds for successive development of additional metastatic tumors in distant organs, which is liable for the majority of cancer-related deaths. On the other hand, these fatal rare cells are capable of providing useful information of cancer patients, since their monitoring and detection is valuable for predicting the response to treatment and prognosis as well as staging of the disease.
The global Circulating Tumor Cells (CTCs) Prognostic Technologies market size is expected to reach US$ 3959.6 million by 2029, growing at a CAGR of 14.9% from 2023 to 2029. The market is mainly driven by the significant applications of Circulating Tumor Cells (CTCs) Prognostic Technologies in various end use industries. The expanding demands from the Prostate Cancer, Breast Cancer, Colorectal Cancer and Lung Cancer, are propelling Circulating Tumor Cells (CTCs) Prognostic Technologies market. Tumor Cell Enrichment, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Tumor Cell Detection segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for Circulating Tumor Cells (CTCs) Prognostic Technologies market, driven by demand from China, the second largest economy with some signs of stabilising, the Circulating Tumor Cells (CTCs) Prognostic Technologies market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Circulating Tumor Cells (CTCs) Prognostic Technologies, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Circulating Tumor Cells (CTCs) Prognostic Technologies market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Circulating Tumor Cells (CTCs) Prognostic Technologies market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Circulating Tumor Cells (CTCs) Prognostic Technologies sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Circulating Tumor Cells (CTCs) Prognostic Technologies covered in this report include AdnaGen, ACDBio, Celula, Epic Sciences, Fluxion Biosciences, Rarecells, Silicon Biosystems and Vitatex, etc.
The global Circulating Tumor Cells (CTCs) Prognostic Technologies market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
AdnaGen
ACDBio
Celula
Epic Sciences
Fluxion Biosciences
Rarecells
Silicon Biosystems
Vitatex
Global Circulating Tumor Cells (CTCs) Prognostic Technologies market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Circulating Tumor Cells (CTCs) Prognostic Technologies market, Segment by Type:
Tumor Cell Enrichment
Tumor Cell Detection
Global Circulating Tumor Cells (CTCs) Prognostic Technologies market, by Application
Prostate Cancer
Breast Cancer
Colorectal Cancer
Lung Cancer
Ovarian Cancer
Pancreatic Cancer
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Circulating Tumor Cells (CTCs) Prognostic Technologies companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Circulating tumor cells (CTCs) are specialized rare cells, which have been shed from a primary solid tumor of the body and circulate in the vasculature system of the body, eventually causing metastasis. CTCs act as the seeds for successive development of additional metastatic tumors in distant organs, which is liable for the majority of cancer-related deaths. On the other hand, these fatal rare cells are capable of providing useful information of cancer patients, since their monitoring and detection is valuable for predicting the response to treatment and prognosis as well as staging of the disease.
The global Circulating Tumor Cells (CTCs) Prognostic Technologies market size is expected to reach US$ 3959.6 million by 2029, growing at a CAGR of 14.9% from 2023 to 2029. The market is mainly driven by the significant applications of Circulating Tumor Cells (CTCs) Prognostic Technologies in various end use industries. The expanding demands from the Prostate Cancer, Breast Cancer, Colorectal Cancer and Lung Cancer, are propelling Circulating Tumor Cells (CTCs) Prognostic Technologies market. Tumor Cell Enrichment, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Tumor Cell Detection segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for Circulating Tumor Cells (CTCs) Prognostic Technologies market, driven by demand from China, the second largest economy with some signs of stabilising, the Circulating Tumor Cells (CTCs) Prognostic Technologies market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Circulating Tumor Cells (CTCs) Prognostic Technologies, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Circulating Tumor Cells (CTCs) Prognostic Technologies market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Circulating Tumor Cells (CTCs) Prognostic Technologies market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Circulating Tumor Cells (CTCs) Prognostic Technologies sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Circulating Tumor Cells (CTCs) Prognostic Technologies covered in this report include AdnaGen, ACDBio, Celula, Epic Sciences, Fluxion Biosciences, Rarecells, Silicon Biosystems and Vitatex, etc.
The global Circulating Tumor Cells (CTCs) Prognostic Technologies market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
AdnaGen
ACDBio
Celula
Epic Sciences
Fluxion Biosciences
Rarecells
Silicon Biosystems
Vitatex
Global Circulating Tumor Cells (CTCs) Prognostic Technologies market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Circulating Tumor Cells (CTCs) Prognostic Technologies market, Segment by Type:
Tumor Cell Enrichment
Tumor Cell Detection
Global Circulating Tumor Cells (CTCs) Prognostic Technologies market, by Application
Prostate Cancer
Breast Cancer
Colorectal Cancer
Lung Cancer
Ovarian Cancer
Pancreatic Cancer
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Circulating Tumor Cells (CTCs) Prognostic Technologies companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Circulating Tumor Cells (CTCs) Prognostic Technologies
1.1 Circulating Tumor Cells (CTCs) Prognostic Technologies Market Overview
1.1.1 Circulating Tumor Cells (CTCs) Prognostic Technologies Product Scope
1.1.2 Circulating Tumor Cells (CTCs) Prognostic Technologies Market Status and Outlook
1.2 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Region (2018-2029)
1.4 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Historic Market Size by Region (2018-2023)
1.5 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size (2018-2029)
1.6.1 North America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size (2018-2029)
1.6.2 Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size (2018-2029)
1.6.3 Asia-Pacific Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size (2018-2029)
1.6.4 Latin America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size (2018-2029)
1.6.5 Middle East & Africa Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size (2018-2029)
2 Circulating Tumor Cells (CTCs) Prognostic Technologies Market by Type
2.1 Introduction
2.1.1 Tumor Cell Enrichment
2.1.2 Tumor Cell Detection
2.2 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Historic Market Size by Type (2018-2023)
2.2.2 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Breakdown by Type (2018-2029)
3 Circulating Tumor Cells (CTCs) Prognostic Technologies Market Overview by Application
3.1 Introduction
3.1.1 Prostate Cancer
3.1.2 Breast Cancer
3.1.3 Colorectal Cancer
3.1.4 Lung Cancer
3.1.5 Ovarian Cancer
3.1.6 Pancreatic Cancer
3.2 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Historic Market Size by Application (2018-2023)
3.2.2 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Breakdown by Application (2018-2029)
4 Circulating Tumor Cells (CTCs) Prognostic Technologies Competition Analysis by Players
4.1 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies as of 2022)
4.3 Date of Key Players Enter into Circulating Tumor Cells (CTCs) Prognostic Technologies Market
4.4 Global Top Players Circulating Tumor Cells (CTCs) Prognostic Technologies Headquarters and Area Served
4.5 Key Players Circulating Tumor Cells (CTCs) Prognostic Technologies Product Solution and Service
4.6 Competitive Status
4.6.1 Circulating Tumor Cells (CTCs) Prognostic Technologies Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 AdnaGen
5.1.1 AdnaGen Profile
5.1.2 AdnaGen Main Business
5.1.3 AdnaGen Circulating Tumor Cells (CTCs) Prognostic Technologies Products, Services and Solutions
5.1.4 AdnaGen Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue (US$ Million) & (2018-2023)
5.1.5 AdnaGen Recent Developments
5.2 ACDBio
5.2.1 ACDBio Profile
5.2.2 ACDBio Main Business
5.2.3 ACDBio Circulating Tumor Cells (CTCs) Prognostic Technologies Products, Services and Solutions
5.2.4 ACDBio Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue (US$ Million) & (2018-2023)
5.2.5 ACDBio Recent Developments
5.3 Celula
5.3.1 Celula Profile
5.3.2 Celula Main Business
5.3.3 Celula Circulating Tumor Cells (CTCs) Prognostic Technologies Products, Services and Solutions
5.3.4 Celula Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue (US$ Million) & (2018-2023)
5.3.5 Epic Sciences Recent Developments
5.4 Epic Sciences
5.4.1 Epic Sciences Profile
5.4.2 Epic Sciences Main Business
5.4.3 Epic Sciences Circulating Tumor Cells (CTCs) Prognostic Technologies Products, Services and Solutions
5.4.4 Epic Sciences Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue (US$ Million) & (2018-2023)
5.4.5 Epic Sciences Recent Developments
5.5 Fluxion Biosciences
5.5.1 Fluxion Biosciences Profile
5.5.2 Fluxion Biosciences Main Business
5.5.3 Fluxion Biosciences Circulating Tumor Cells (CTCs) Prognostic Technologies Products, Services and Solutions
5.5.4 Fluxion Biosciences Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue (US$ Million) & (2018-2023)
5.5.5 Fluxion Biosciences Recent Developments
5.6 Rarecells
5.6.1 Rarecells Profile
5.6.2 Rarecells Main Business
5.6.3 Rarecells Circulating Tumor Cells (CTCs) Prognostic Technologies Products, Services and Solutions
5.6.4 Rarecells Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue (US$ Million) & (2018-2023)
5.6.5 Rarecells Recent Developments
5.7 Silicon Biosystems
5.7.1 Silicon Biosystems Profile
5.7.2 Silicon Biosystems Main Business
5.7.3 Silicon Biosystems Circulating Tumor Cells (CTCs) Prognostic Technologies Products, Services and Solutions
5.7.4 Silicon Biosystems Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue (US$ Million) & (2018-2023)
5.7.5 Silicon Biosystems Recent Developments
5.8 Vitatex
5.8.1 Vitatex Profile
5.8.2 Vitatex Main Business
5.8.3 Vitatex Circulating Tumor Cells (CTCs) Prognostic Technologies Products, Services and Solutions
5.8.4 Vitatex Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue (US$ Million) & (2018-2023)
5.8.5 Vitatex Recent Developments
6 North America
6.1 North America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Circulating Tumor Cells (CTCs) Prognostic Technologies Market Dynamics
11.1 Circulating Tumor Cells (CTCs) Prognostic Technologies Industry Trends
11.2 Circulating Tumor Cells (CTCs) Prognostic Technologies Market Drivers
11.3 Circulating Tumor Cells (CTCs) Prognostic Technologies Market Challenges
11.4 Circulating Tumor Cells (CTCs) Prognostic Technologies Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
